Central nervous system diseases are a group of neurological disorders that affect the structure or function of the brain, optic nerve or spinal cord, which collectively form the central nervous system.
A large range of conditions can affect the neurons, the building block of the nervous system, as well as the supporting glial cells such as the myelin forming cells. Neuronal and glial damage lead to severe disabilities by affecting our memories, personality and ability to move, see and speak.
The brain is very sensitive to damage. Preserving brain connections (healthy neurons and neuroglial cells) is critical to preserve cognitive function and daily activities.
CNS drugs currently represent a substantial prescription drug-market area with yearly sales exceeding USD 50bn, covering all major diseases including Multiple Sclerosis, which alone represents approximately USD 20bn.
Today, hundreds of thousands to millions of patients affected by serious disabilities have no or limited treatment offer, and new disease-modifiers drugs are awaited.
Bionure’s initial focus areas are Acute Optic Neuritis (AON) and Multiple Sclerosis (MS), for which there are very high unmet medical needs. The current standards of care include anti-inflammatory drugs and/or immunomodulators, both of which reduce inflammation but do not adequately protect the neurons nor repair the nerve damage.